Field trials with Oltipraz against Schistosoma mansoni in the Gezira Irrigated Area, Sudan.

Oltipraz, a new antischistosomal drug, has been field tested in Sudan for acceptability, tolerance and efficacy against Schistosoma mansoni. One hundred and fifty-one school children aged 7 to 12 years were selected for treatment with 20 mg/kg Oltipraz, 78 with a single dose and 73 with a split dose, on the same day. The drug was well tolerated except that 20 children in one school complained of fingertip pain.

Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan.

A field trial was conducted in Sudan to evaluate the acceptability and efficacy of praziquantel given to schoolchildren aged 7-11 years who were all infected with both Schistosoma mansoni and S. haematobium. Two dosage regimes were compared, a single dose of 40 mg/kg bodyweight, and a divided dose 2 X 20 mg/kg given 4-6 h apart.

Dose-finding trial using Oltipraz to treat schoolchildren infected with Schistosoma mansoni in Gezira, Sudan.

A field trial has been carried out in Sudan to determine the optimum dosage regimen for the use of Oltipraz in the treatment of Schistosoma mansoni in schoolchildren. A total of 294 children were treated in six groups to test 15 mg/kg, 20 mg/kg, and 25 mg/kg, using a single oral dose and a divided dose taken some 6 h apart. The children were interviewed before and then 24 h after treatment to determine the prevalence of drug-induced side-effects.